Treatment-related morbidity in phase III RTOG studies of extended-field irradiation for carcinoma of the prostate

Pilepich, Miljenko V.; Krall, John M.; George, Frederick W.; Asbell, Sucha O.; Plenk, H. D.; Johnson, Richard J.; Stetz, JoAnn; Zinninger, M.; Walz, Bruce J.

doi:10.1016/0360-3016(84)90263-3

Cited by 64 publications

(14 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The frequency of late radiation complications (42%) is comparable to the figures in phase III RTOG studies [17]. Most of the complications were mild and required no special treatment.…”

Section: Resultssupporting

confidence: 67%

Comparison of Endocrine and Radiation Therapy in Locally Advanced Prostatic Cancer

Aro

Haapiainen²,

Kajanti³

et al. 1988

Eur Urol

View full text Add to dashboard Cite

“…The frequency of late radiation complications (42%) is comparable to the figures in phase III RTOG studies [17]. Most of the complications were mild and required no special treatment.…”

Section: Resultssupporting

confidence: 67%

Comparison of Endocrine and Radiation Therapy in Locally Advanced Prostatic Cancer

Aro

Haapiainen²,

Kajanti³

et al. 1988

Eur Urol

View full text Add to dashboard Cite

“…The rate of ⩾G2 rectal toxicity after radiotherapy has been reported as 5.1% in the analysis of patients who enrolled in the RTOG 75-06 and 77-06 trials (Pilepich et al , 1984). However, a lower total dose of radiation of ∼65 Gy was used in those trials, so their results cannot be compared with recent data.…”

Section: Discussionmentioning

confidence: 99%

“…The incidence of ⩾G2 late GU toxicity was ∼5% in the RTOG 75-06 and 77-06 trials (Pilepich et al , 1984). In the abovementioned phase III clinical trial reported by Pollack et al (2002), the rates of G2 and G3 late GU toxicities in the 151 patients in the 78 Gy group were 10% and 3%, respectively, whereas the rates of G2 and G3 late GU toxicities in the 150 patients in 70 Gy group were 7% and 1%, respectively.…”

Section: Discussionmentioning

confidence: 99%

Phase I/II trial of definitive carbon ion radiotherapy for prostate cancer: evaluation of shortening of treatment period to 3 weeks

Nomiya¹,

Tsuji²,

Maruyama³

et al. 2014

Br J Cancer

View full text Add to dashboard Cite

Background:The purpose of this study was to evaluate the feasibility of a new shortened 3-week treatment schedule of carbon ion radiotherapy (CIRT) for prostate cancer.Methods:Beginning in May 2010, patients with T1b–T3bN0M0, histologically proven prostate adenocarcinoma were enrolled in the phase II trial of CIRT. Patients received 51.6 GyE in 12 fractions over 3 weeks (protocol 1002). The primary end point was defined as the incidence of late adverse events that were evaluated based on the Common Terminology Criteria for Adverse Events version 4.0. Biochemical failure was determined using the Phoenix definition (nadir +2.0 ng ml−1).Results:Forty-six patients were enrolled, and all patients were included in the analysis. The number of low-, intermediate-, and high-risk patients was 12 (26%), 9 (20%), and 25 (54%), respectively. The median follow-up period of surviving patients was 32.3 months. Two patients had intercurrent death without recurrence, and the remaining 44 patients were alive at the time of this analysis. In the analysis of late toxicities, grade 1 (G1) rectal haemorrhage was observed in 3 (7%) patients. The incidence of G1 haematuria was observed in 6 (13%) patients, and G1 urinary frequency was observed in 17 (37%) patients. No ⩾G2 late toxicities were observed. In the analysis of acute toxicities, 2 (4%) patients showed G2 urinary frequency, and no other G2 acute toxicities were observed.Conclusions:The new shortened CIRT schedule over 3 weeks was considered as feasible. The analysis of long-term outcome is warranted.

show abstract

“…There are also reports that 5–15% of the patients who receive abdominal or pelvic irradiation will develop chronic radiation enteritis. The overall frequency of radiation cystitis 1 year after treatment of bladder cancer is 9–21% [36]. In our study, 11 and 7 patients (total 29.5%) in the preoperative radiotherapy group developed complications of chronic radiation enteritis and cystitis, respectively.…”

Section: Discussionmentioning

confidence: 52%

What Is the Value of Surgical Intervention for Sacral Metastases?

Yang

et al. 2016

PLoS ONE

View full text Add to dashboard Cite

ObjectiveTo investigate the impact of surgery on local control and quality of life for patients with sacral metastases and to determine whether the complications of surgery were acceptable.MethodsCurettage for metastatic lesions of the sacrum was performed in 154 patients with obvious sacral nerve compression symptoms between July 1997 and July 2014. Potential risk factors were evaluated in univariate analysis for associations with local control; multivariate conditional logistic regression was used to identify the combined effects. Complications were recorded. The pre- and postoperative visual analogue scale of pain, Eastern Cooperative Oncology Group (ECOG) scores, and quality of life scores were collected to evaluate the impact of surgery.ResultsThe cumulative survival rates were 71.8%, 41.1%, and 22.5% and the local control rates were 95.4%, 90.9%, and 79.4% at 6, 12, and 24 months, respectively. Tumors with rapid growth, the lack of preoperative radiotherapy, and application of aortic balloon occlusion were significantly associated with good local control. There were 29 (18.8%) complications related to surgery. The mean pain scores were 7.04 preoperatively, 1.66 at 1 month postoperatively (p = 0.003), and 1.51 at 3 months postoperatively (p = 0.002). The mean ECOG scores were 2.82 preoperatively and 1.47 3 months postoperatively (p < 0.001). There were significant improvements from preoperatively to 3 months postoperatively in global health status (43.3 vs. 52.1), pain (62.0 vs. 33.2), and constipation (51.4 vs. 30.3) (p < 0.001).ConclusionsSurgery for sacral metastasis is effective to palliate pain rapidly and improve constipation and quality of life and has a low rate of complications.

show abstract

Treatment-related morbidity in phase III RTOG studies of extended-field irradiation for carcinoma of the prostate

Cited by 64 publications

References 3 publications

Comparison of Endocrine and Radiation Therapy in Locally Advanced Prostatic Cancer

Comparison of Endocrine and Radiation Therapy in Locally Advanced Prostatic Cancer

Phase I/II trial of definitive carbon ion radiotherapy for prostate cancer: evaluation of shortening of treatment period to 3 weeks

What Is the Value of Surgical Intervention for Sacral Metastases?

Contact Info

Product

Resources

About